Surgery, chemotherapy and radiotherapy remain the three primary approaches for treating the majority of cancers. Although the primary aim of radiotherapy is to inhibit tumor cell proliferation and induce tumor cell death by inducing DNA double-strand breaks, it is also known to have a number of immunological effects, the manipulation of which could enhance clinical efficacy. Recent insights into the immunomodulatory capacity of tumours, and the development of approaches to therapeutically exploit these have prompted the emergence of a range of immunotherapeutic approaches for inducing and enhancing robust, protective anti-tumor immunity. Combining radiotherapy with immunotherapy (radioimmunotherapy) therefore has significant clinical potential. The aim of this Research Topic is to collate primary articles, reviews and opinion pieces on the complex reciprocal relationships between the immune system, tumors and the tumour microenvironment, and the stimulatory and suppressive effects of radiotherapy on innate and adaptive immunity in the pre-clinical and clinical settings.

Translational Biotechnology: A Journey from Laboratory to Clinics presents an integrative and multidisciplinary approach to biotechnology to help readers bridge the gaps between fundamental and functional research. The book provides state-of-the-art and integrative views of translational biotechnology by covering topics from basic concepts to novel methodologies. Topics discussed include biotechnology-based therapeutics, pathway and target discovery, biological therapeutic modalities, translational bioinformatics, and system and synthetic biology. Additional sections cover drug discovery, precision medicine and the socioeconomic impact of translational biotechnology. This book is valuable for bioinformaticians, biotechnologists, and members of the biomedical field who are interested in learning more about this promising field. Explains biotechnology in a different light by using an application-oriented approach Discusses practical approaches in the development of precision medicine tools, systems and dynamical medicine approaches Promotes research in the field of biotechnology that is translational in nature, cost-effective and readily available to the community

This represents the third volume in a series on cancer markers pub lished by the Humana Press. The first volume, published in 1980, stressed the relationship of development and cancer as reflected in the production of markers by cancer that are also produced by normal cells during fetal development. The concept that cancer represents a problem of differentiation was introduced by Barry Pierce in describing differenti ation of teratocarcinomas. Highlighted were lymphocyte markers, alphafetoprotein, carcinoembryonic antigen, ectopic hormones, enzymes and isozymes, pregnancy proteins, and fibronectin. The second volume, published in 1982 and coedited with Britta Wahren, focused on the diagnostic use of oncological markers in human cancers, which were systematically treated on an organ by organ basis. At that time, the application of monoclonal antibodies to the identification of cancer markers was still in a very preliminary stage. A general introduc tion to monoclonal antibodies to human tumor antigens was given there by William Raschke, and other authors included coverage of those mark ers then detectable by monoclonal antibodies in their chapters.

This book consists of 4 volumes containing about 70 chapters covering all the major aspects of the growing area of nanomedicine. Leading scientists from 15 countries cover all major areas of nanobiomedical research — materials for nanomedicine, application of nanomedicine in therapy of various diseases, use of nanomedicines for diagnostic purposes, technology of nanomedicines, and new trends in nanobiomedical research.This is the first detailed handbook specifically addressing various aspects of nanobiomedicine. Readers are treated to cutting-edge research and the newest data from leading researchers in this area.